NINO RAINUSSO to Male
This is a "connection" page, showing publications NINO RAINUSSO has written about Male.
Connection Strength
0.125
-
Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. Pediatr Blood Cancer. 2019 04; 66(4):e27579.
Score: 0.026
-
Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012 Mar; 19(3):212-7.
Score: 0.016
-
Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors. Pediatr Blood Cancer. 2025 Apr; 72(4):e31557.
Score: 0.010
-
Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study. Radiother Oncol. 2024 06; 195:110270.
Score: 0.009
-
Genomic analysis and preclinical xenograft model development identify potential therapeutic targets for MYOD1-mutant soft-tissue sarcoma of childhood. J Pathol. 2021 09; 255(1):52-61.
Score: 0.008
-
Targeting PAK4 Inhibits Ras-Mediated Signaling and Multiple Oncogenic Pathways in High-Risk Rhabdomyosarcoma. Cancer Res. 2021 01 01; 81(1):199-212.
Score: 0.007
-
Assessing the left atrium of childhood cancer survivors. Int J Cardiovasc Imaging. 2021 Jan; 37(1):155-162.
Score: 0.007
-
Improving reproducibility of left ventricular ejection fraction in pediatric oncology patients: less is more. Int J Cardiovasc Imaging. 2020 Oct; 36(10):1887-1895.
Score: 0.007
-
Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma. Pediatr Blood Cancer. 2020 04; 67(4):e28123.
Score: 0.007
-
Tegavivint and the ?-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 11 01; 111(11):1216-1227.
Score: 0.007
-
Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb; 65(2).
Score: 0.006
-
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.
Score: 0.005
-
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma. Cancer Med. 2015 Jul; 4(7):977-88.
Score: 0.005
-
T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013 Mar; 21(3):629-37.
Score: 0.004